Cargando…

An Integrative Approach to Dissect the Drug Resistance Mechanism of the H172Y Mutation of SARS-CoV-2 Main Protease

Nirmatrelvir is an orally available inhibitor of SARS-CoV-2 main protease (Mpro) and the main ingredient of PAXLOVID, a drug approved by FDA for high-risk COVID-19 patients. Recently, a rare natural mutation, H172Y, was found to significantly reduce nirmatrelvir’s inhibitory activity. As the COVID-1...

Descripción completa

Detalles Bibliográficos
Autores principales: Clayton, Joseph, de Oliveira, Vinicius Martins, Ibraham, Mohamed Fouad, Sun, Xinyuanyuan, Mahinthichaichan, Paween, Shen, Mingzhe, Hilgenfeld, Rolf, Shen, Jana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9387124/
https://www.ncbi.nlm.nih.gov/pubmed/35982652
http://dx.doi.org/10.1101/2022.07.31.502215